Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib Plus Enzalutamide as First Line Treatment for mCRPC
NCT06582628Phase 2Recruiting
- Sponsor
- OncoSur
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of talazoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by OncoSur. Started Jul 2024; status: recruiting.
02
Drugs
talazoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06582628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582628.